The future of plant drug discovery

John Littleton

doi:10.1517/17460441.2.5.673

The future of plant drug discovery

John Littleton

Psychology

Producción científica: Review article › revisión exhaustiva

15 Citas (Scopus)

Resumen

To have a future in the pharmaceutical industry, plant drug discovery must compete with combinatorial chemistry and high-throughput pharmacologic screening (HTPS). Plant functional genomics coupled with HTPS may achieve this; thus, functional biology can identify 'libraries' of candidate plant species from which individuals can be prioritized by 'differential HTPS'. The full genomic potential of a species for bioactivity can be accessed by cellular mutagenesis and elicitation, with HTPS identifying clones with novel activity. The comparison of 'positive' clonal phenotypes with their almost identical 'negatives' facilitates the identification of active compounds and 'genomic' products. The logical conclusion is to use combinatorial genomics together with HTPS to direct plant cellular 'evolution' continuously towards metabolites with specific pharmacologic activity. Mankind would then become the orchestrator of plant secondary metabolism, rather than its passive beneficiary.

Idioma original	English
Páginas (desde-hasta)	673-683
Número de páginas	11
Publicación	Expert Opinion on Drug Discovery
Volumen	2
N.º	5
DOI	https://doi.org/10.1517/17460441.2.5.673
Estado	Published - may 2007

Nota bibliográfica

Funding Information:
Several colleagues have contributed to the author’s education and to these ideas, most notably D Falcone (plant molecular biology) and T Rogers (high-throughput screening of plant extracts). M Davies (Director of the Kentucky Tobacco Research and Development Center [KTRDC]) has encouraged the research throughout and additional input has come from P Crooks (natural product chemistry) and P Lawless (plant evolutionary biology). Funding is acknowledged from KTRDC, Kentucky Science and Technology Corporation and from NIH (RO1AA012600, R41AA014555, R41AA4554, R41AA015475, R41CA115093).

Financiación

Several colleagues have contributed to the author’s education and to these ideas, most notably D Falcone (plant molecular biology) and T Rogers (high-throughput screening of plant extracts). M Davies (Director of the Kentucky Tobacco Research and Development Center [KTRDC]) has encouraged the research throughout and additional input has come from P Crooks (natural product chemistry) and P Lawless (plant evolutionary biology). Funding is acknowledged from KTRDC, Kentucky Science and Technology Corporation and from NIH (RO1AA012600, R41AA014555, R41AA4554, R41AA015475, R41CA115093).

Financiadores	Número del financiador
Kentucky Science and Technology Corporation
National Institutes of Health (NIH)	R41CA115093, RO1AA012600, R41AA015475, R41AA014555, R41AA4554
The Kentucky Tobacco Research and Development Center

ASJC Scopus subject areas

Drug Discovery

Acceder al documento

10.1517/17460441.2.5.673

Otros archivos y enlaces

Citar esto

@article{843e98aac0a9425aa15a838c3776c3a7,

title = "The future of plant drug discovery",

abstract = "To have a future in the pharmaceutical industry, plant drug discovery must compete with combinatorial chemistry and high-throughput pharmacologic screening (HTPS). Plant functional genomics coupled with HTPS may achieve this; thus, functional biology can identify 'libraries' of candidate plant species from which individuals can be prioritized by 'differential HTPS'. The full genomic potential of a species for bioactivity can be accessed by cellular mutagenesis and elicitation, with HTPS identifying clones with novel activity. The comparison of 'positive' clonal phenotypes with their almost identical 'negatives' facilitates the identification of active compounds and 'genomic' products. The logical conclusion is to use combinatorial genomics together with HTPS to direct plant cellular 'evolution' continuously towards metabolites with specific pharmacologic activity. Mankind would then become the orchestrator of plant secondary metabolism, rather than its passive beneficiary.",

keywords = "Elicitation, Evolution, Genomics, Mutagenesis, Pharmacology, Screening, Secondary metabolism",

author = "John Littleton",

note = "Funding Information: Several colleagues have contributed to the author{\textquoteright}s education and to these ideas, most notably D Falcone (plant molecular biology) and T Rogers (high-throughput screening of plant extracts). M Davies (Director of the Kentucky Tobacco Research and Development Center [KTRDC]) has encouraged the research throughout and additional input has come from P Crooks (natural product chemistry) and P Lawless (plant evolutionary biology). Funding is acknowledged from KTRDC, Kentucky Science and Technology Corporation and from NIH (RO1AA012600, R41AA014555, R41AA4554, R41AA015475, R41CA115093).",

year = "2007",

month = may,

doi = "10.1517/17460441.2.5.673",

language = "English",

volume = "2",

pages = "673--683",

number = "5",

}

TY - JOUR

T1 - The future of plant drug discovery

AU - Littleton, John

N1 - Funding Information: Several colleagues have contributed to the author’s education and to these ideas, most notably D Falcone (plant molecular biology) and T Rogers (high-throughput screening of plant extracts). M Davies (Director of the Kentucky Tobacco Research and Development Center [KTRDC]) has encouraged the research throughout and additional input has come from P Crooks (natural product chemistry) and P Lawless (plant evolutionary biology). Funding is acknowledged from KTRDC, Kentucky Science and Technology Corporation and from NIH (RO1AA012600, R41AA014555, R41AA4554, R41AA015475, R41CA115093).

PY - 2007/5

Y1 - 2007/5

N2 - To have a future in the pharmaceutical industry, plant drug discovery must compete with combinatorial chemistry and high-throughput pharmacologic screening (HTPS). Plant functional genomics coupled with HTPS may achieve this; thus, functional biology can identify 'libraries' of candidate plant species from which individuals can be prioritized by 'differential HTPS'. The full genomic potential of a species for bioactivity can be accessed by cellular mutagenesis and elicitation, with HTPS identifying clones with novel activity. The comparison of 'positive' clonal phenotypes with their almost identical 'negatives' facilitates the identification of active compounds and 'genomic' products. The logical conclusion is to use combinatorial genomics together with HTPS to direct plant cellular 'evolution' continuously towards metabolites with specific pharmacologic activity. Mankind would then become the orchestrator of plant secondary metabolism, rather than its passive beneficiary.

AB - To have a future in the pharmaceutical industry, plant drug discovery must compete with combinatorial chemistry and high-throughput pharmacologic screening (HTPS). Plant functional genomics coupled with HTPS may achieve this; thus, functional biology can identify 'libraries' of candidate plant species from which individuals can be prioritized by 'differential HTPS'. The full genomic potential of a species for bioactivity can be accessed by cellular mutagenesis and elicitation, with HTPS identifying clones with novel activity. The comparison of 'positive' clonal phenotypes with their almost identical 'negatives' facilitates the identification of active compounds and 'genomic' products. The logical conclusion is to use combinatorial genomics together with HTPS to direct plant cellular 'evolution' continuously towards metabolites with specific pharmacologic activity. Mankind would then become the orchestrator of plant secondary metabolism, rather than its passive beneficiary.

KW - Elicitation

KW - Evolution

KW - Genomics

KW - Mutagenesis

KW - Pharmacology

KW - Screening

KW - Secondary metabolism

UR - https://www.scopus.com/pages/publications/34447566982

UR - https://www.scopus.com/pages/publications/34447566982#tab=citedBy

U2 - 10.1517/17460441.2.5.673

DO - 10.1517/17460441.2.5.673

M3 - Review article

C2 - 23488957

AN - SCOPUS:34447566982

SN - 1746-0441

VL - 2

SP - 673

EP - 683

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

IS - 5

ER -

The future of plant drug discovery

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto